Browse

The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?